235 related articles for article (PubMed ID: 21114538)
1. APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells.
Ali D; Jönsson-Videsäter K; Deneberg S; Bengtzén S; Nahi H; Paul C; Lehmann S
Eur J Haematol; 2011 Mar; 86(3):206-15. PubMed ID: 21114538
[TBL] [Abstract][Full Text] [Related]
2. Mutated and non-mutated TP53 as targets in the treatment of leukaemia.
Nahi H; Selivanova G; Lehmann S; Möllgård L; Bengtzen S; Concha H; Svensson A; Wiman KG; Merup M; Paul C
Br J Haematol; 2008 May; 141(4):445-53. PubMed ID: 18341636
[TBL] [Abstract][Full Text] [Related]
3. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
4. PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion.
Nahi H; Merup M; Lehmann S; Bengtzen S; Möllgård L; Selivanova G; Wiman KG; Paul C
Br J Haematol; 2006 Jan; 132(2):230-6. PubMed ID: 16398657
[TBL] [Abstract][Full Text] [Related]
5. Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death.
Heo SK; Noh EK; Yu HM; Kim DK; Seo HJ; Lee YJ; Cheon J; Koh SJ; Min YJ; Choi Y; Jo JC
BMC Cancer; 2020 Dec; 20(1):1193. PubMed ID: 33276759
[TBL] [Abstract][Full Text] [Related]
6. Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells.
Niu X; Zhao J; Ma J; Xie C; Edwards H; Wang G; Caldwell JT; Xiang S; Zhang X; Chu R; Wang ZJ; Lin H; Taub JW; Ge Y
Clin Cancer Res; 2016 Sep; 22(17):4440-51. PubMed ID: 27103402
[TBL] [Abstract][Full Text] [Related]
7. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
8. Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia.
Moujalled DM; Pomilio G; Ghiurau C; Ivey A; Salmon J; Rijal S; Macraild S; Zhang L; Teh TC; Tiong IS; Lan P; Chanrion M; Claperon A; Rocchetti F; Zichi A; Kraus-Berthier L; Wang Y; Halilovic E; Morris E; Colland F; Segal D; Huang D; Roberts AW; Maragno AL; Lessene G; Geneste O; Wei AH
Leukemia; 2019 Apr; 33(4):905-917. PubMed ID: 30214012
[TBL] [Abstract][Full Text] [Related]
9. Increased p21/WAF-1 and p53 protein levels following sequential three drug combination regimen of fludarabine, cytarabine and docetaxel induces apoptosis in human leukemia cells.
Avramis VI; Nandy P; Kwock R; Solorzano MM; Mukherjee SK; Danenberg P; Cohen LJ
Anticancer Res; 1998; 18(4A):2327-38. PubMed ID: 9703875
[TBL] [Abstract][Full Text] [Related]
10. Ajoene, a garlic-derived natural compound, enhances chemotherapy-induced apoptosis in human myeloid leukaemia CD34-positive resistant cells.
Ahmed N; Laverick L; Sammons J; Zhang H; Maslin DJ; Hassan HT
Anticancer Res; 2001; 21(5):3519-23. PubMed ID: 11848518
[TBL] [Abstract][Full Text] [Related]
11. Synergistic effects of PRIMA-1
Maslah N; Salomao N; Drevon L; Verger E; Partouche N; Ly P; Aubin P; Naoui N; Schlageter MH; Bally C; Miekoutima E; Rahmé R; Lehmann-Che J; Ades L; Fenaux P; Cassinat B; Giraudier S
Haematologica; 2020 Jun; 105(6):1539-1551. PubMed ID: 31488557
[TBL] [Abstract][Full Text] [Related]
12. Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
Liu F; Knight T; Su Y; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Sun L; Ge Y
Target Oncol; 2019 Jun; 14(3):351-364. PubMed ID: 31115744
[TBL] [Abstract][Full Text] [Related]
13. Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells.
Ruvolo PP; Ruvolo VR; Benton CB; AlRawi A; Burks JK; Schober W; Rolke J; Tidmarsh G; Hail N; Davis RE; Andreeff M
Biochim Biophys Acta; 2016 Apr; 1863(4):562-71. PubMed ID: 26704388
[TBL] [Abstract][Full Text] [Related]
14. Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells.
Wergeland L; Sjøholt G; Haaland I; Hovland R; Bruserud Ø; Gjertsen BT
Mol Cancer; 2007 May; 6():33. PubMed ID: 17498302
[TBL] [Abstract][Full Text] [Related]
15. Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia.
Del Poeta G; Bruno A; Del Principe MI; Venditti A; Maurillo L; Buccisano F; Stasi R; Neri B; Luciano F; Siniscalchi A; de Fabritiis P; Amadori S
Curr Cancer Drug Targets; 2008 May; 8(3):207-22. PubMed ID: 18473734
[TBL] [Abstract][Full Text] [Related]
16. The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells.
Nechiporuk T; Kurtz SE; Nikolova O; Liu T; Jones CL; D'Alessandro A; Culp-Hill R; d'Almeida A; Joshi SK; Rosenberg M; Tognon CE; Danilov AV; Druker BJ; Chang BH; McWeeney SK; Tyner JW
Cancer Discov; 2019 Jul; 9(7):910-925. PubMed ID: 31048320
[TBL] [Abstract][Full Text] [Related]
17. 5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis.
Jin S; Cojocari D; Purkal JJ; Popovic R; Talaty NN; Xiao Y; Solomon LR; Boghaert ER; Leverson JD; Phillips DC
Clin Cancer Res; 2020 Jul; 26(13):3371-3383. PubMed ID: 32054729
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.
Zhao J; Niu X; Li X; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Ge Y
Oncotarget; 2016 Jun; 7(23):34785-99. PubMed ID: 27166183
[TBL] [Abstract][Full Text] [Related]
19. Impact of loss of BH3-only proteins on the development and treatment of MLL-fusion gene-driven AML in mice.
Bilardi RA; Anstee NS; Glaser SP; Robati M; Vandenberg CJ; Cory S
Cell Death Dis; 2016 Sep; 7(9):e2351. PubMed ID: 27584789
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of autophagy as a treatment strategy for p53 wild-type acute myeloid leukemia.
Folkerts H; Hilgendorf S; Wierenga ATJ; Jaques J; Mulder AB; Coffer PJ; Schuringa JJ; Vellenga E
Cell Death Dis; 2017 Jul; 8(7):e2927. PubMed ID: 28703806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
